Literature DB >> 18332233

Eliminating the complete response penalty from myeloma response assessment.

Sagar Lonial, Morie A Gertz.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18332233     DOI： 10.1182/blood-2008-01-132456

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma.

Authors:  Cheng E Chee; Shaji Kumar; Dirk R Larson; Robert A Kyle; Angela Dispenzieri; Morie A Gertz; Colin L Colby; S Vincent Rajkumar
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

2.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

3.  Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma.

Authors:  Eric W Schaefer; Shaji Kumar; Angela Dispenzieri; Jacob B Allred; Morie A Gertz; Martha Q Lacy; S Vincent Rajkumar; Sumithra J Mandrekar
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.